Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
09:55am, Thursday, 06'th Mar 2025
BOOT, STRL, DECK & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
10:45am, Wednesday, 05'th Mar 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BMRN or CSLLY: Which Is the Better Value Stock Right Now?
12:46pm, Friday, 28'th Feb 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
10:50am, Friday, 28'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
09:00am, Tuesday, 25'th Feb 2025
SAN RAFAEL, Calif. , Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
04:05pm, Monday, 24'th Feb 2025
SAN RAFAEL, Calif. , Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P.
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
01:45pm, Monday, 24'th Feb 2025
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?
10:55am, Monday, 24'th Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the posit
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
05:56pm, Thursday, 20'th Feb 2025
BioMarin Pharmaceutical (BMRN 4.75%) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
10:26am, Thursday, 20'th Feb 2025
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Why Is BioMarin Stock Trading Higher On Thursday?
09:39am, Thursday, 20'th Feb 2025
On Wednesday, BioMarin Pharmaceutical Inc. BMRN reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents.
BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript
08:08pm, Wednesday, 19'th Feb 2025
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Muel
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
06:31pm, Wednesday, 19'th Feb 2025
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compa
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates
06:20pm, Wednesday, 19'th Feb 2025
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.49 per share a year ago.
BioMarin: EPS Surges Past Expectations
04:50pm, Wednesday, 19'th Feb 2025
BioMarin Pharmaceutical (BMRN 1.16%), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped analysts
